Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net income including noncontrolling interests	$ 21,938	$ 3,384
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:
Non-cash change in estimated fair value of contingent liabilities	7,277	3,261
Realized gain on sale of short-term investment	(502)	(968)
Gain on write-off of assets	0	(16)
Depreciation and amortization	1,296	1,337
Amortization of discount on investments, net	(34)	0
Amortization of debt discount and issuance fees	5,058	0
Stock-based compensation	6,675	5,093
Non-cash upfront fee	0	(1,211)
Deferred income taxes	268	6
Accretion of note payable	16	169
Gain on deconsolidation of Viking Therapeutics, Inc.	(28,190)	0
Loss on equity investment in Viking Therapeutics, Inc.	870	0
Changes in operating assets and liabilities:
Accounts receivable	7,102	(911)
Inventory	(533)	575
Other current assets	(462)	(136)
Other long-term assets	(598)	(231)
Accounts payable and accrued liabilities	(3,107)	(3,743)
Restricted investments	661	0
Deferred revenue	(110)	(24)
Net cash provided by operating activities	17,625	6,585
Investing activities
Purchase of commercial license rights	(4,030)	0
Payments to CVR holders and other contingency payments	(3,663)	(1,668)
Purchases of property and equipment	(27)	0
Purchase of short-term investments	(60,432)	0
Purchase of Viking common stock	(9,000)	0
Proceeds from sale of property and equipment	1	125
Reduction of cash due to deconsolidation of Viking Therapeutics, Inc.	(247)	0
Proceeds from sale of short-term investments	2,378	1,155
Other, net	0	(1)
Net cash used in investing activities	(75,020)	(389)
Financing activities
Repayment of debt	0	(6,947)
Net proceeds from stock option exercises and ESPP	5,430	3,648
Net cash provided by (used in) financing activities	5,430	(3,299)
Net (decrease) increase in cash and cash equivalents	(51,965)	2,897
Cash and cash equivalents at beginning of period	160,203	11,639
Cash and cash equivalents at end of period	108,238	14,536
Supplemental disclosure of cash flow information
Interest paid	903	212
Taxes paid	13	3
Supplemental schedule of non-cash activity
Unrealized gain on AFS investments	$ 7,844	$ 3,095